AGP Executive Report
Last update: 21 minutes agoMedicinal Cannabis Market Watch: Australia’s Botanix (ASX:BOT) got a US notice of allowance covering a crystalline form of its active substance, strengthening its patent “wall” as it pushes repeat prescriptions. Supply & Scale: BioLargo (ASX:BLS) says exclusive medicinal cannabis supply deals and a new UK production site are turning spare capacity into contracted export volume. Clinical Pipeline: Avecho (ASX:AVE) cleared a key insomnia trial checkpoint, with Australian rights already licensed to a global generics group. Regulatory Pressure: Vitura (ASX:VIT) faces tighter prescribing expectations after guidance reshaped compliance around cannabis access pathways, while Little Green Pharma (ASX:LGP) warns domestic dispensing volumes have cooled as regulators scrutinize how patients actually reach products. Research & Innovation: A study reports cannabis sativa hairy-root nanovesicles showed early immunomodulatory and anti-tumor potential in mice. Public Health: California officials warn about kratom products, especially more concentrated versions with opioid-like effects. Policy & Taxes: Connecticut is set to switch cannabis taxation from THC-based to a flat 10.75% gross receipts excise, with a state analysis suggesting lower revenue. Data Security: Spanish cannabis club software exposed Irish passports in a vulnerability, raising privacy and cyber-risk concerns for club systems.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
